News in the Life Sciences Industry

BURLINGTON, Mass., Feb. 21, 2019 /PRNewswire/ -- PharmaEssentia today announced that the European Commission (EC) has approved Besremi(®) (ropeginterferon alfa-2b, P1101) as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. The European market authorization... Read more ››

TAIPEI, Taiwan, February 21, 2019 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today the topline results of FP-001 LMIS (Leuprolide Mesylate Injectable Suspension) 25 mg phase 3 clinical trial, an open-label, single-arm study in subjects with Prostate Carcinoma.... Read more ››

GYEONGGI, South Korea, Feb. 14, 2019 /PRNewswire/ -- SK Biopharmaceuticals and Arvelle Therapeutics GmbH today announced that they have entered into an exclusive licensing agreement for Arvelle to develop and commercialize cenobamate in Europe. Cenobamate is a novel, small molecule investigational... Read more ››

TAIPEI, Taiwan, Feb. 14, 2019 /PRNewswire/ -- A team led by Dr. Chi-Huey Wong, Distinguished Research Fellow, Academia Sinica in Taiwan, in collaboration with OBI scientists, has demonstrated in a recent study that the Globo-series glycosphingolipid (GSL) antigens: Globo-H, SSEA-3, and SSEA-4... Read more ››

HSINCHU, Taiwan, Jan. 21, 2019 /PRNewswire/ --

TAIPEI, Taiwan, Jan. 2, 2019 /PRNewswire/ -- APRINOIA Therapeutics, a clinical-stage biotechnology company developing therapeutics and diagnostic imaging tools for neurodegenerative diseases announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation.... Read more ››

NEW YORK, Dec. 20, 2018 /PRNewswire/ -- S1 Biopharma, Inc. (S1) announced today that the European Patent Office has granted a European Patent for the Company's proprietary dual-mechanistic therapy Lorexys(TM) for hypoactive sexual desire disorder. A corresponding patent was previously... Read more ››

JOHANNESBURG, Dec. 3, 2018 /PRNewswire/ --